November 12th 2024
Camizestrant showed better progression-free survival than fulvestrant across various subgroups of patients with advanced breast cancer.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Avon Funds Breast Cancer Awareness Program for Orthodox Jewish Women
December 1st 1996NEW YORK--The Avon Breast Health Access Fund has awarded a grant of $23,961 to Cancer Care for a program to increase awareness of the life-saving benefits of early breast cancer detection among low-income Orthodox Jewish women in New York City. Cancer Care is a nonprofit organization that provides free professional services to people with cancer and their families,
New Edition of NABCO Breast Cancer Resource List Is Now Available
December 1st 1996NEW YORK--The National Alliance of Breast Cancer Organizations (NABCO) has just published the 1996-1997 edition of the NABCO Breast Cancer Resource List, made possible through an educational grant from Glaxo Wellcome Inc
Breast Cancer Incidence and Mortality--United States, 1992
December 1st 1996Breast cancer is the most commonly diagnosed nondermatologic cancer and the second leading cause of cancer-related deaths among women in the United States. In 1996, a total of 184,300 new cases of and 44,300 deaths from invasive breast cancer are projected among women. To assess trends in incidence and death rates for breast cancer among US women, the CDC analyzed national incidence data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program and death-certificate data from the CDC's National Center for Health Statistics (NCHS).
Success of Sentinel Lymph Node Biopsy in Melanoma Leads to Test in Breast Cancer
December 1st 1996A national study underway at Virginia Commonwealth University (VCU) will determine whether breast cancer patients can benefit from a biopsy procedure that has been successfully used for skin cancer patients. Patients with melanoma, the most serious kind of skin cancer, have benefited from an advance that has reduced the pain and complications of surgery performed to ascertain whether their cancer has spread.
High Bone Mineral Density Associated With More Than a Doubling of Breast Cancer Risk
December 1st 1996Long-term exposure to estrogen, as measured by bone mineral density, can more than double the risk of breast cancer, according to a study led by researchers at the University of Pittsburgh and reported in the November 5th issue of The Journal of the American Medical Association. Estrogen replacement therapy is often prescribed in women during menopause to reduce hot flashes and other uncomfortable symptoms of this transitional period.
Breast Cancer Group Recommends Return Of Funds, in Attempt To Limit its Focus
December 1st 1996WASHINGTON--In an extraordinary decision, the steering committee of the National Action Plan on Breast Cancer (NAPBC) voted to reject nearly the entire $14.75 million that Congress provided it for use in fiscal year 1997.
Factor Analysis of New Symptom Scale in Breast Cancer Finds Six Clusters
November 27th 1996WAYNE, NJ-Initial testing of the Symptom Experience Scale (SES), designed to measure women's experiences of symptoms associated with treatment for breast cancer, found six factors that used all 24 SES items and accounted for 83% of the variance, report Nelda Samarel, EdD, RN, of William Paterson College of New Jersey, and her colleagues.
New Breast Cancer Patient Resource Is Available
November 1st 1996WILMINGTON, Del-The Breast Cancer Patient Education Service, recently established by Zeneca Pharmaceuticals, allows breast cancer patients and their families to obtain patient education materials on tamoxifen (Nolvadex) with one phone call.
Indigent Women With Breast Cancer Are Often Not Referred for Breast Reconstruction
November 1st 1996The option of reconstruction after mastectomy for breast cancer is often not discussed with indigent patients, according to a study presented at the 65th Annual Meeting of the American Society of Plastic and Reconstructive Surgeons (ASPRS) held in Dallas, Texas.
Klausner Cites Breast Cancer Progress in Jo Oberstar Lecture
November 1st 1996WASHINGTON--Breast cancer mortality continues to drop among white women in the United States, Canada, and Great Britain, and, for the first time, it has dropped in black American women, NCI Director Richard Klausner said in his delivery of the 6th Annual Jo Oberstar Memorial Lecture at the George Washington University School of Medicine.
Workplace Cancer Screening Program Saves Lives, Money
November 1st 1996NEW YORK-Screening for breast cancer in the workplace saves money as well as lives, according to a study commissioned by Zeneca Inc. To emphasize this important message to business, the results were presented in a news conference held on Wall Street at the New York Stock Exchange.
NIH to Evaluate New Data on Breast Cancer Screening in Younger Women
November 1st 1996BETHESDA, Md-NIH plans a consensus development conference to assess the most recent data on the efficacy of mammography in screening women age 40 to 49 for breast cancer. The agency plans to convene the conference on January 21-23, 1997, on the NIH Bethesda campus.
DNA Squencing Locates p53 Mutations in Breast Cancer
November 1st 1996NEW YORK-DNA sequencing is the gold standard for determining the presence or absence of p53 mutations in breast tumors, said Jorge A. Leon, PhD, corporate director for biotechnology research and development, Corning Nichols Institute/Corning Clinical Laboratories.
Book Profiles 32 Women Who Fought Breast Cancer
October 1st 1996BIRMINGHAM, Ala--In 1994, the Comprehensive Cancer Center of the University of Alabama at Birmingham commissioned photojournalist Melissa Springer to create an exhibit celebrating breast cancer survivors. Her finished project has now been published as A Tribe of Warrior Women.
New RIA Blood Test Predicts Breast Cancer Recurrence
October 1st 1996CHICAGO--The Truquant BR RIA blood test (manufactured by Biomira Diagnostics, Inc.) has been shown to be a highly specific predictor of recurrent breast cancer. In clinical trials, positive test results predicted relapse 83% of the time, providing as much as a 12-month (average, 5 month) warning over clinical symptoms and/or other diagnostic methods for breast cancer recurrence.
New Cancer Gene Marker Could Help Tailor Chemotherapy for Breast Cancer
October 1st 1996Researchers at Duke University Comprehensive Cancer Center have found that a newly identified liver cancer gene is also defective in more aggressive breast tumors that may not respond to certain common types of chemotherapy.
Media Attention to Prostate Cancer Lags Behind Breast Cancer, Advocate Says
October 1st 1996NEW YORK--Michael Korda, best-selling author and editor-in-chief and vice president of Simon and Schuster, had never heard of PSA until a routine test showed that his was elevated; he had never thought about prostate cancer as something that could happen to him. After all, he was asymptomatic, a "fanatic exerciser," had given up smoking 20 years ago, and ate carefully.
Women, Kids from the Heartland Express Feelings about Breast Cancer
October 1st 1996OKLAHOMA CITY--Project Wo-man, a committee of the American Cancer Society (ACS)--has published a book depicting the experiences of Oklahoma women with breast cancer as expressed by the women themselves, their friends, children, and other loved ones through stories, photographs, and artwork (see illustrations at right and on page 1).
Kopans Receives the Kushner Writing Award
October 1st 1996BETHESDA, Md--Daniel B. Kopans, MD, of the Department of Radiology, Massachusetts General Hospital and Harvard Medical School, has received the 1996 Rose Kushner Award for Writing Achievement in the Field of Breast Cancer for best scientific article.
Tamoxifen Prevention Study Enrollment Nears Completion
October 1st 1996BETHESDA, Md--The Breast Cancer Prevention Trial (BCPT), launched in 1992, will need fewer women than originally estimated for completion. Although planned for 16,000 women, the trial now has more than 12,000 enrolled, and needs only another 1,000 for completion, which is expected next year.
Assessing Women's Potential Risk of Developing Breast Cancer
October 1st 1996This well-written article can benefit only from reinforcement of a few of its major points, some supplemental discussion about the important role of biologic models in understanding and managing breast cancer development, and a note about the critical need for research and perspectives from the social sciences concerning this subject. I say "only" because this article beautifully and clearly explores some of the language of epidemiology critical to the subject, language which is becoming increasingly important in routine medical practice. Practitioners and, increasingly, the public (medical "consumers") are concerned with risks and numbers.
Optimal Duration of Tamoxifen Requires More Investigation
October 1st 1996An expert panel of nine international cancer researchers and practicing oncolo-gists met in Boston to discuss the past, present, and future uses of antiestrogens in the treatment of breast cancer. This article represents the first in a series of reports based on the symposium presentations that will be featured in subsequent issues of Oncology News International.The symposium was sponsored by Zeneca Pharmaceuticals.
Amy Langer on Leave of Absence From NABCO After Automobile Accident
October 1st 1996NEW YORK--Amy S. Langer, of the National Alliance of Breast Cancer Organizations (NABCO), has taken a leave of absence from her position as executive director, due to extensive injuries suffered in a serious car accident in upstate New York.
M.D. Anderson Unveils Mammography Van
October 1st 1996HOUSTON--Just in time for Breast Cancer Awareness Month, The University of Texas M.D. Anderson Cancer Center has unveiled a mobile mam-mography program that will bring screening mammography to corporate and community locations throughout the Houston area.
AgeAwareness Group Urges the Media to Keep Breast Cancer Issues on the Public Agenda
September 1st 1996NEW YORK--Public discussion has played a large part in the recent declines in breast cancer mortality, say the sponsors of National Breast Cancer Awareness Month (NBCAM), and they urge the media to keep breast cancer on the public agenda.